ClinicalTrials.gg
Not yet recruitingNCT06217133HRVUpdated Jan 22, 2024

Heart Rate Variability of Premature Newborn

An interventional study of CPAP in Autonomic Nervous System Imbalance, sponsored by Federal University of Uberlandia. Not yet recruiting. Open to participants aged 28 Weeks to 32 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Federal University of Uberlandia · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
28 Weeks to 32 Weeks
Sex
All
01

Study summary

To analyze the effects of two CPAP methods on the HRV of PTNBs during their routine routine in the HCUFU neonatal ICU. This is a randomized clinical trial, with controlled groups and cross over with healthy term newborns (RNT) as a control group admitted to the HC-UFU rooming-in and premature newborns (PTRN), between 28 and 32 weeks pregnant women with nasal CPAP group admitted to the neonatal ICU of the same hospital. The HRV recorded by the POLAR® RS800cx cardiac monitor will be analyzed, with a sampling rate of 1000 Hz.

The main question[s] it aims to answer are:

  • Is there a difference in heart rate variability between newborns using conventional nasal CPAP and nasal bubble CPAP?
  • Is it possible to conclude that one of the methods has a greater sympathetic or parasympathetic tone compared to the other?

Premature participants will be in the incubators in a supine position with 30 minutes rest after the last handling. Each data collection will last 60 minutes and will be carried out three times a day in the morning, afternoon and night shifts, for each 1-hour collection, HRV will be analyzed in 12 5-minute intervals, establishing an average for each variable of the data. HRV during a 1-hour period.

The researchers will compare the conventional CPAP and bubble CPAP group according to randomization.

  • In the control group, data collection will be carried out in the Rooming Room in a single reference collection lasting 20 minutes, and analyzed in 4 5-minute intervals.
  • The participant selected for conventional CPAP will receive conventional CPAP for 24 hours, then receive bubble CPAP for 24 hours the following day. The opposite will be done for the participant drawn for CPAP bubbles.

The comparison between the conventional CPAP and bubble CPAP groups will occur to find out whether it is possible to identify the type of non-invasive ventilation that allows an increase in HRV and parasympathetic tone variables, as well as a reduction in sympathetic tone variables and the stress index of premature babies.

02

Conditions studied

  • Autonomic Nervous System Imbalance

Keywords

  • Heart rate variability
  • Neonatal intensive care unit
  • Non-invasive ventilation
03

In context

Lead sponsor

Federal University of Uberlandia is the lead sponsor of 61 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All preterm infants between 28 and 32 weeks of gestation using nasal CPAP and who are at least 8 and at most 12 days old will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • hemodynamic instability,
  • hydroelectrolyte disorders that influence cardiac function,
  • post-operative,
  • congenital abnormalities,
  • pulmonary hypertension,
  • decompensated ductus arteriosus,
  • untreated atelectasis,
  • pneumothorax,
  • newborns who are using drains, whether chest or abdominal,
  • presence of necrotizing enterocolitis
  • grade 3 nasal septum injury,
  • signal captured without the necessary quality to be used in research,
  • premature babies who, for whatever reason, do not have two collections carried out on consecutive days until the twelfth day of life.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • No intervention
    control group

    The analysis of heart rate variability will be carried out in theIn the control group (NT), data collection will be carried out in the Rooming Room in a single reference collection lasting 20 minutes, and analyzed in 4 5-minute intervals. Newborns will be full term and will be in the supine position, lying in the common crib and resting. All collections for this group will be carried out in the afternoon on a day to be agreed with the mother or responsible companion.

  • Active comparator
    CPAP Group

    The analysis of heart rate variability will be carried out in the in the CPAP group, conventional and in the bubble CPAP.

    Device: CPAP

Interventions

  • DeviceCPAP

    Conventional CPAP will be administered according to the unit's routine on ventilators of different brands and models according to service availability. Binary prongs, from brands available in the service, will be used as an interface without touching the nasal septum with the size recommended by the manufacturer and in accordance with the protocol established in the unit. TThe CPAP bubbles will be administered using the CPAP NEONATAL BABYPAP® MODEL 1150 S equipment, which is an electromedical device for non-invasive ventilatory assistance for newborns that generates continuous pressure in the airways (CPAP) controlled by means of a column of water that bubbles, through a flow of heated and humidified medical gas mixture supplied by a breathing circuit to the patient's nasal passage.

    Also known as: continuous positive airway pressure

06

What researchers measure

Primary outcomes

  1. HRV variables in time domains

    The time domain variables are: average of RR intervals (Mean RR) expressed in milliseconds (ms); average beats per minute (Mean HR) expressed in (bpm); standard deviation of all normal RR intervals (SDNN) expressed in (ms); square root of the mean square differences between successive RR intervals (RMSSD) expressed in (ms); percentage of adjacent RR intervals with a difference in duration greater than 50 ms (pNN50) expressed in percentage (%).

    Time frame: A total of two evaluation days will be carried out, which will be divided into: 1 full hour in the morning, afternoon and evening, totaling 3 hours for each consecutive evaluation day

  2. Frequency domain variables

    The frequency domain variables are: very low frequency (VLF) expressed in hertz (Hz); low frequency (LF) expressed in Hz; high frequency (HF) expressed in Hz.

    Time frame: A total of two evaluation days will be carried out, which will be divided into: 1 full hour in the morning, afternoon and evening, totaling 3 hours for each consecutive evaluation day

  3. The non-linear parameters of heart rate variability

    The non-linear parameters of heart rate variability are: short-term (instantaneous) beat-to-beat RR variability of the Poincaré plot (SD1) expressed in milliseconds (ms); long-term (continuous) beat-to-beat variability of the Poincaré plot (SD2) also expressed in ms and the SD2/SD1 ratio.

    Time frame: total of two evaluation days will be carried out, which will be divided into: 1 full hour in the morning, afternoon and evening, totaling 3 hours for each consecutive evaluation day

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06217133
Lead sponsor
Federal University of Uberlandia
Collaborators
Adriano de Oliveira Andrade
Responsible party
Letícia de Queiroz Martins (Letícia de Queiroz Martins, Federal University of Uberlandia) — Principal investigator
First posted
Jan 22, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
May 31, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Jan 22, 2024

Study contacts

Letícia de Queiroz Martins, 3
Contact
leticiaqm.fisio@hotmail.com
55 (34) 32182112
Adriano de Oliveira Andrade, 3
Contact
adriano@ufu.br
55 (34) 3239-4709
Lilian Rodrigues de Abreu Macedo, 3
study chair · Federal University of Uberlandia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion